Active Filter(s):
Details:
Under the agreement, Merck will receive an exclusive license to RGX-202 (ompenaclid), currently in Phase II development for RAS-mutated advanced or metastatic colorectal cancer, outside of the United States and an option to co-develop and co-promote ompenaclid in the US.
Lead Product(s): RGX-202,Bevacizumab,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: RGX-202
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Undisclosed Upfront Cash: $45.0 million
Deal Type: Licensing Agreement January 04, 2024
Details:
RGX-104 (abequolixron) is an orally administered small molecule agonist of the Liver X Receptor (LXR) which activates expression of the APOE tumor suppressor protein. Abequolixron is currently being tested in a Phase 1b/2 clinical trial in several lung cancer etc.
Lead Product(s): RGX-104,Pembrolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: RGX-104
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
Proceeds will support the development of lead candidate RGX-202-01 (“RGX-202”), an oral small molecule inhibitor of SLC6a8 to treat RAS mutant advanced colorectal cancer and RGX-104, an oral small molecule activator of LXR/APOE to treat lung and endometrial cancer.
Lead Product(s): RGX-202-01,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area: Oncology Product Name: RGX-202-01
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Sands Capital
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing July 11, 2022
Details:
RGX-202-01 is an oral, potential first-in-class small molecule inhibitor of SLC6a8, a creatine transporter that drives colorectal cancer and certain other cancers’ progression.
Lead Product(s): RGX-202-01,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area: Oncology Product Name: RGX-202-01
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
Details:
RGX-202-01 is an oral, potential first-in-class small molecule inhibitor of SLC6a8, a creatine transporter that drives colorectal cancer and certain other cancers’ progression.
Lead Product(s): RGX-202-01,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area: Oncology Product Name: RGX-202-01
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
RGX-202-01, oral small-molecule inhibitor of SLC6A8 that induces apoptosis of colorectal cancer cell, is being tested in combination with the FOLFIRI and bevacizumab in a Phase 1b clinical trial for 2nd line treatment of patients with cancer whose tumors express CKB.
Lead Product(s): RGX-202-01,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area: Oncology Product Name: RGX-202-01
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022